Technical Analysis for HOWL - Werewolf Therapeutics, Inc.

Grade Last Price % Change Price Change
C 6.02 -1.95% -0.12
HOWL closed down 1.95 percent on Monday, March 18, 2024, on 48 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
Earnings due: Mar 21
*** please verify all earnings dates ***
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Down

Date Alert Name Type % Chg
Bollinger Band Squeeze Range Contraction 0.00%
Oversold Stochastic Weakness 0.00%
Bollinger Band Squeeze Range Contraction -1.95%
NR7 Range Contraction -1.95%
NR7-2 Range Contraction -1.95%
Oversold Stochastic Weakness -1.95%
Bollinger Band Squeeze Range Contraction -1.47%
NR7 Range Contraction -1.47%
Doji - Bullish? Reversal -1.47%
Oversold Stochastic Weakness -1.47%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 11 hours ago
Up 2% about 12 hours ago
Down 2 % about 14 hours ago
Down 1% about 14 hours ago
Fell Below Previous Day's Low about 15 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Werewolf Therapeutics, Inc. Description

Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. It offers PREDATOR, a platform of protein engineering technology to design and engineer the future of immuno-oncology biotherapeutics for patients. The company's lead product candidates include WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule for the treatment of relapsed or refractory advanced or metastatic solid tumors or lymphoma. It also develops WTX-613, a conditionally activated interferon alpha INDUKINE molecule for the treatment of solid tumors and hematologic malignancies. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Cancer Life Sciences Solid Tumors Health Sciences Treatment Of Cancer Cancer Immunotherapy Lymphoma Hematologic Malignancies Advanced Solid Tumors Metastatic Solid Tumors

Is HOWL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 8.1939
52 Week Low 1.5735
Average Volume 261,146
200-Day Moving Average 3.54
50-Day Moving Average 5.85
20-Day Moving Average 6.73
10-Day Moving Average 6.48
Average True Range 0.54
RSI (14) 45.36
ADX 21.2
+DI 17.79
-DI 22.06
Chandelier Exit (Long, 3 ATRs) 6.58
Chandelier Exit (Short, 3 ATRs) 7.60
Upper Bollinger Bands 7.65
Lower Bollinger Band 5.81
Percent B (%b) 0.11
BandWidth 27.24
MACD Line 0.08
MACD Signal Line 0.26
MACD Histogram -0.1799
Fundamentals Value
Market Cap 217.88 Million
Num Shares 36.2 Million
EPS -1.10
Price-to-Earnings (P/E) Ratio -5.47
Price-to-Sales 8.61
Price-to-Book 2.22
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.46
Resistance 3 (R3) 6.50 6.39 6.39
Resistance 2 (R2) 6.39 6.27 6.37 6.36
Resistance 1 (R1) 6.20 6.20 6.15 6.17 6.34
Pivot Point 6.09 6.09 6.06 6.07 6.09
Support 1 (S1) 5.91 5.98 5.85 5.87 5.70
Support 2 (S2) 5.80 5.91 5.78 5.68
Support 3 (S3) 5.61 5.80 5.65
Support 4 (S4) 5.58